Author

María Chaparro

LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

María Chaparro  et al.

SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS
SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS

María Chaparro  et al.

PROFILING OF HUMAN CIRCULATING DENDRITIC CELLS AND MONOCYTES SUBSETS DISCRIMINATES TYPE AND MUCOSAL STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PROFILING OF HUMAN CIRCULATING DENDRITIC CELLS AND MONOCYTES SUBSETS DISCRIMINATES TYPE AND MUCOSAL STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

María Chaparro  et al.

THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB

María Chaparro  et al.

PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU
PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU

María Chaparro  et al.

EFFECTS OF ANTI-TNF AND ANTI-INTERLEUKINS 12 AND 23 DRUGS ON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN INFLAMMATORY BOWEL DISEASE
EFFECTS OF ANTI-TNF AND ANTI-INTERLEUKINS 12 AND 23 DRUGS ON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN INFLAMMATORY BOWEL DISEASE

María Chaparro  et al.

IMMUNOLOGICAL EFFECTS OF HEPATITIS B VIRUS VACCINATION IN INFLAMMATORY BOWEL DISEASE PATIENTS
IMMUNOLOGICAL EFFECTS OF HEPATITIS B VIRUS VACCINATION IN INFLAMMATORY BOWEL DISEASE PATIENTS

María Chaparro  et al.

HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE AMONG PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR AND CONCOMITANT THERAPIES: RESULTS FROM THE ETRASIMOD ELEVATE UC CLINICAL PROGRAMME
HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE AMONG PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR AND CONCOMITANT THERAPIES: RESULTS FROM THE ETRASIMOD ELEVATE UC CLINICAL PROGRAMME

María Chaparro  et al.

IDENTIFICATION OF CONSTITUTIVE MODIFICATIONS IN PLASMA CELLS AND B LYMPHOCYTES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
IDENTIFICATION OF CONSTITUTIVE MODIFICATIONS IN PLASMA CELLS AND B LYMPHOCYTES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

María Chaparro  et al.

EFFECTS OF ANTI-TNF-ALPHA AND ANTI-ALPHA4BETA7 DRUGS ON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN INFLAMMATORY BOWEL DISEASE
EFFECTS OF ANTI-TNF-ALPHA AND ANTI-ALPHA4BETA7 DRUGS ON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN INFLAMMATORY BOWEL DISEASE

María Chaparro  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY

María Chaparro  et al.

EX VIVO EFFECTS OF INFLIXIMAB ON THE LONG NON-CODING RNAS EXPRESSION LEVELS IN CROHN´S DISEASE
EX VIVO EFFECTS OF INFLIXIMAB ON THE LONG NON-CODING RNAS EXPRESSION LEVELS IN CROHN´S DISEASE

María Chaparro  et al.

URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY
URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY

María Chaparro  et al.

MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

María Chaparro  et al.

DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY
DURABILITY AND SAFETY OF UPADACITINIB IN CROHN’S DISEASE AND ULCERATIVE COLITIS IN REAL LIFE: PRELIMINARY RESULTS FROM A SPANISH NATIONWIDE STUDY

María Chaparro  et al.

IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH
IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH

María Chaparro  et al.

ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES
ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES

María Chaparro  et al.

EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)
EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)

María Chaparro  et al.

PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

María Chaparro  et al.

Item 21 - 39 / 39
1
2